Study Title

bayer

A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)

Study Details

Description:

Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY3546828) is a new type of treatment under development for men with mCRPC who have already received available treatments or have few treatment options available. It works by binding to a protein on the surface of the cancer cells called prostate specific membrane antigen (PSMA). As it gives off a type of radioactivity that travels a very short distance, it kills the nearby (cancer) cells that express PSMA.

Sponsor:

Bayer

Contacts:

Bayer Clinical Trials Contact

clinical-trials-contact@bayer.com

(+)1-888-84 22937

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468